Healthcare, Pharma & Life Sciences

AKASA Launches Autonomous AI Coding Covering 10% of U.S. Discharges

Image
AKASA Launches Autonomous AI Coding Covering 10% of U.S. Discharges

South San Francisco, Calif. – October 02, 2026 -- AKASA has launched an autonomous AI platform for inpatient medical coding and clinical documentation integrity (CDI), expanding beyond its existing prebill review tools after inpatient volume processed by the company grew nearly 6x over the past year.

AKASA's health system customers now cover 10% of U.S. inpatient discharges

The company's customer base collectively represents more than $180 billion in aggregate net patient revenue and roughly 10% of all U.S. inpatient discharges. The growth has been driven by adoption of AKASA's existing AI-powered prebill review products, which the company says created the volume and performance data needed to move into fully autonomous coding.

Quotient Sciences, Acesion Pharma Partner on AI Drug Formulation

Image
Quotient Sciences, Acesion Pharma Partner on AI Drug Formulation

Nottingham, England – October 02, 2026 -- Quotient Sciences and Copenhagen-based Acesion Pharma have launched a collaboration to apply AI-enhanced formulation development to Acesion's early-stage pipeline of small molecules targeting atrial fibrillation, a condition affecting an estimated 50-60 million people globally.

AI tool uses Bayesian optimization to screen drug formulations for clinical success

The collaboration deploys Quotient Sciences' new AI-enhanced formulation development solution within its Translational Pharmaceutics platform, applying active machine learning with Bayesian optimization to identify and prioritize drug products most likely to succeed in clinical testing. The approach is designed to compress early clinical decision-making timelines for sponsors developing new treatments.

Tianjin University's BCI Device Cuts Diagnosis Time to 30 Minutes

Tianjin, China – October 02, 2026 -- Tianjin University's "Shengong-Shengao" system has become China's first approved brain-computer interface (BCI) medical device for diagnosing cognitive impairment, cutting diagnosis time for conditions like hydrocephalus from days to just 30 minutes. The milestone marks a commercial breakthrough as TJU, China's first modern university, marks its 131st anniversary on October 2, 2026.

Shengong device line moves from lab to clinical wards nationwide

Developed by a team led by Professor Liu Xiuyun, the Shengong-Shengao system received regulatory approval and has already been joined by more than 20 additional devices in the Shengong series now deployed in clinical settings. The university states the devices have delivered measurable benefits to thousands of patients, signaling rapid translation of university research into deployable medical hardware.

Ascletis' ASC36_35FDC Shows Stronger Weight Loss Than Rival Combos in Preclinical Data

Image
Ascletis' ASC36_35FDC Shows Stronger Weight Loss Than Rival Combos in Preclinical Data

Hong Kong – – October 02, 2026 -- Ascletis Pharma Inc. (HKEX: 1672) presented preclinical data showing its ASC36_35FDC injectable combination drove a 24.8% body-weight reduction in a diet-induced obesity rat model on Day 14, outperforming two competitor co-formulations tested under identical dosing conditions.

The data were unveiled in a short oral discussion at the 62nd European Association for the Study of Diabetes (EASD) Annual Meeting, held September 28–October 2, 2026, in Milan, Italy.

Amen Clinics Study Finds Postpartum Depression Has Distinct Brain Patterns

Image
Amen Clinics Study Finds Postpartum Depression Has Distinct Brain Patterns

Costa Mesa, Calif. – October 02, 2026 -- Nearly 40% of women with postpartum depression showed a hyperfrontal/anterior cingulate cortex brain-activity pattern, more than double the 19.4% rate found in patients with major depression, according to new research from Dr. Daniel Amen and colleagues at Amen Clinics.

Brain scan comparison covers 26,135 patients across two depression groups

Researchers analyzed brain SPECT imaging scans from 58 women diagnosed with postpartum depression (PPD) and compared them against scans from 26,077 people with major depression. Each scan was classified into one of six brain-function categories: hyperfrontal/ACC, limbic, hypofrontal, toxic/diffuse low perfusion, brain trauma/acquired injury, or mixed patterns.

Lundbeck to Present Phase III MSA Data, Parkinson's Pipeline at MDS 2026

Valby – October 02, 2026 -- H. Lundbeck A/S will present late-breaking Phase III data on its multiple system atrophy (MSA) drug candidate amlenetug alongside new Parkinson's disease pipeline results at the International Congress of Parkinson's Disease and Movement Disorders (MDS) 2026 in Seoul, South Korea, running October 4-8.

MASCOT trial enrolled 401 participants across a global Phase III program

The late-breaking oral presentation will detail baseline characteristics of participants in MASCOT (NCT06706622), Lundbeck's ongoing Phase III trial of amlenetug in MSA. The trial enrolled 401 participants with clinically probable or established MSA, covering both MSA-C and MSA-P subtypes, across sites in North America, Europe, Asia and Australia. The double-blind treatment period runs 72 weeks, comparing high- and low-dose amlenetug against placebo, with results expected in Q3 2027.

Samfara Acquires Danish Controlled-Substance API Maker Chr. Olesen Synthesis

Image
Samfara Acquires Danish Controlled-Substance API Maker Chr. Olesen Synthesis

London – October 02, 2026 -- Samfara has completed the acquisition of Chr. Olesen Synthesis, a Danish manufacturer of controlled-substance active pharmaceutical ingredients, marking the London-based life sciences investment firm's first deal. The transaction sees Samfara buy the business from Chr. Olesen and funds managed by Signet Healthcare Partners, with Chief Executive Thomas Moestrup co-investing alongside the new owner. Financial terms were not disclosed.

Chr. Olesen Synthesis supplies opioid-disorder and ADHD treatment ingredients globally

Based near Copenhagen, Chr. Olesen Synthesis develops and manufactures APIs and advanced intermediates specialising in controlled substances, including buprenorphine for opioid use disorder and lisdexamfetamine for ADHD. Its cGMP-certified plant in Hvidovre has been in commercial production since 2015, supplying pharmaceutical companies across Europe, North America and the Middle East.

Novartis Pays Abogen $575M Upfront for mRNA T-Cell Engager Rights

Suzhou – October 02, 2026 -- Novartis has agreed to pay Abogen Biosciences an upfront fee of USD 575 million to secure worldwide rights to ABO2203, an mRNA-encoded CD19xCD3 T-cell engager for autoimmune diseases, with total deal value reaching up to approximately USD 7.2 billion if all milestones and options are exercised.

Novartis secures exclusive worldwide license to Abogen's lead autoimmune asset ABO2203

The licensing and option agreement grants Novartis an exclusive global license to ABO2203, which Abogen describes as the first mRNA-encoded T-cell engager to enter clinical evaluation for autoimmune diseases. The molecule uses mRNA to direct endogenous production of T-cell engagers in vivo, targeting B-cell depletion through a mechanism the companies say differs from traditional recombinant T-cell engagers.

Hansoh's Olatorepatide Shows 19.3% Weight Loss at Week 48 in Phase III Trial

Milan – October 02, 2026 -- Hansoh Pharma's dual-biased GLP-1/GIP receptor agonist Olatorepatide (HS-20094) achieved a mean weight loss of 19.3% at Week 48 in the 15 mg dose group of a Phase III Chinese trial, with no plateau observed in the weight-loss curve.

The data, presented as a Late-breaking Abstract oral presentation at the European Association for the Study of Diabetes (EASD) Annual Meeting running September 28 to October 2, 2026 in Milan, come from the LIGHTEN study, a multicenter, randomized, double-blind, placebo-controlled trial enrolling 604 Chinese adults with overweight or obesity.

Trial enrolled 604 participants across four dose arms over 48 weeks

Participants with a BMI of 28 kg/m2 or above, or 24-28 kg/m2 with a weight-related comorbidity, were randomized 1:1:1:1 to once-weekly subcutaneous Olatorepatide at 5mg, 10mg or 15mg, or placebo. A total of 90.1% completed the full 48-week treatment period.

MontoHealth Builds AI Action Layer to Automate Patient Workflows

Image
MontoHealth Builds AI Action Layer to Automate Patient Workflows

San Francisco -- October 02, 2026 -- MontoHealth is developing an AI-driven action layer designed to execute routine healthcare tasks—not just discuss them—across existing hospital and clinic software systems.

MontoHealth targets the gap between digitized records and automated work

Despite two decades of healthcare digitization, tasks such as rescheduling an appointment, routing a prescription refill, coordinating a referral or resolving an insurance query still require manual phone calls and handoffs across disconnected systems. Healthcare organizations typically operate EHRs, scheduling platforms, billing systems and patient portals as separate applications, each governed by distinct privacy and security controls. MontoHealth argues that digitizing a workflow has not equated to automating it, leaving staff to perform the connective work between systems.